---
title: "US IPO Weekly Recap:  Two sizable IPOs price, a multibillion-dollar deal joins the pipeline, and Anthropic sets terms"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305512749.md"
description: "US IPO Weekly Recap highlights two priced deals and Anthropic's upcoming Nasdaq debut. vVardis (VVVV) raised $175M at a $1.1B cap, finishing down 8.3%. Windward Bio (WWB) raised $175M at a $1.0B cap, surging 67.6% on positive Phase 2 data. Meanwhile, RZRA postponed its IPO. Market snapshots show the Renaissance IPO Index up 1.2% YTD versus the S&P 500's 11.8% gain."
datetime: "2026-11-13T22:45:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305512749.md)
  - [en](https://longbridge.com/en/news/305512749.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305512749.md)
generator: "portal-rs"
---

# US IPO Weekly Recap:  Two sizable IPOs price, a multibillion-dollar deal joins the pipeline, and Anthropic sets terms

Two IPOs priced this week, while one biotech (RZRA) postponed. Two IPOs and three SPACs submitted filings.

The biggest headline was about what’s to come: **Anthropic** (ANT) set terms and kicked off the roadshow for its highly anticipated IPO on Tuesday. It’s slated to begin trading on the Nasdaq on Thursday, November 19.

Leading the week’s pricings, cavity treatment provider **vVardis** (VVVV) offered more shares than anticipated but priced below the range to raise $175 million at a $1.1 billion market cap. Based in Switzerland, vVardis develops and sells Curodont, a peptide-based treatment for early-stage cavities that is applied in a dental office in five minutes or less, with no drilling or needles. Its US product, Curodont Repair Fluoride Plus, is marketed as an OTC drug under an FDA monograph and generates the vast majority of revenue. The company is fast growing but expects to remain unprofitable in the near term. vVardis finished down 8.3%.

Swiss biotech **Windward Bio Group** (WWB) priced at the midpoint to raise $175 million at a $1.0 billion market cap. Windward is developing two in-licensed antibodies for asthma, COPD, and atopic dermatitis that need less frequent dosing than current treatments. Its lead candidate, WIN378, targets TSLP (the same target as Tezspire) and is designed for twice-yearly dosing versus every four weeks for Tezspire. The company reported some positive interim data in WIN378's Phase 2 asthma trial, and is moving on to two Phase 3 trials that are expected to read out in the 1H29. Windward Bio finished up 67.6%.

**IPO Market Snapshot**The Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 11/12/2026, the Renaissance IPO Index was up 1.2% year-to-date, while the S&P 500 was up 11.8%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include SpaceX (SPCX) and Astera Labs (ALAB). The Renaissance International IPO Index was up 6.0% year-to-date, while the ACWX was up 10.4%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Galderma and CATL.

### Related Stocks

- [ANT.US](https://longbridge.com/en/quote/ANT.US.md)
- [VVVV.US](https://longbridge.com/en/quote/VVVV.US.md)
- [WWB.US](https://longbridge.com/en/quote/WWB.US.md)
- [.SPX.US](https://longbridge.com/en/quote/.SPX.US.md)
- [300750.CN](https://longbridge.com/en/quote/300750.CN.md)
- [ALAB.US](https://longbridge.com/en/quote/ALAB.US.md)
- [SPCX.US](https://longbridge.com/en/quote/SPCX.US.md)

## Related News & Research

- [Anthropic IPO guide: Everything you need to know](https://longbridge.com/en/news/305691440.md)
- [Anthropic’s Valuation Target Has Slipped From $2 Trillion to Under $1.5 Trillion. Here’s Why](https://longbridge.com/en/news/305493732.md)
- [Arthur Hayes buys crypto risk before Anthropic listing but keeps exits close](https://longbridge.com/en/news/305403579.md)
- [Anthropic's IPO is about six times oversubscribed, Bloomberg News reports](https://longbridge.com/en/news/305371908.md)
- [Novo Holdings-backed Windward Bio valued at $1 billion as shares rise in Nasdaq debut](https://longbridge.com/en/news/305492826.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**